Cargando…

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease

OBJECTIVE: We aimed to estimate the cost-effectiveness, burden of disease and budget impact of inclisiran added to standard-of-care lipid-lowering therapy in the real-world secondary cardiovascular prevention population in Switzerland. METHODS: An open-cohort Markov model captured event risks by sex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galactionova, Katya, Salari, Paola, Mattli, Renato, Rachamin, Yael, Meier, Rahel, Schwenkglenks, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300545/ https://www.ncbi.nlm.nih.gov/pubmed/35723806 http://dx.doi.org/10.1007/s40273-022-01152-8

Ejemplares similares

Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
por: Galactionova, Katya, et al.
Publicado: (2022)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Burden of smoking on disease-specific mortality, DALYs, costs: the case of a high-income European country
por: Farcher, Renato, et al.
Publicado: (2023)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
por: Meier, Rahel, et al.
Publicado: (2020)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Guideline Concordance of Statin Treatment Decisions: A Retrospective Cohort Study
por: Rachamin, Yael, et al.
Publicado: (2020)

General practitioners’ consultation counts and associated factors in Swiss primary care – A retrospective observational study
por: Rachamin, Yael, et al.
Publicado: (2019)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion
por: Sendi, Pedram, et al.
Publicado: (2021)

Heart failure epidemiology and treatment in primary care: a retrospective cross‐sectional study
por: Rachamin, Yael, et al.
Publicado: (2020)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Trends and between-Physician Variation in Laboratory Testing: A Retrospective Longitudinal Study in General Practice
por: Schumacher, Lisa D., et al.
Publicado: (2020)

Prescription Rates, Polypharmacy and Prescriber Variability in Swiss General Practice—A Cross-Sectional Database Study
por: Rachamin, Yael, et al.
Publicado: (2022)

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
por: Galactionova, Katya, et al.
Publicado: (2015)

Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany
por: Jud, Sebastian M., et al.
Publicado: (2020)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
por: Schur, Nadine, et al.
Publicado: (2021)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
por: Galactionova, Katya, et al.
Publicado: (2022)

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
por: Wong, Robert J., et al.
Publicado: (2021)

Real-World Disease Burden of Chronic Urticaria and Vaccine Hesitancy
por: Ban, Ga-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9n6rvvn86k1k6d7uo7bp3icrcu